Inspira Technologies (IINN) OXY announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration-cleared INSPIRA ART100 system at a new and additional leading U.S. academic medical center. This deployment expands Inspira Technologies’ presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center’s clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Sets Up $2 Million At-the-Market Equity Program with A.G.P.
- Inspira Technologies announces strategic commercial showcase of Inspira ART100
- Inspira Technologies receives noncompliance notification from Nasdaq
- Inspira Technologies Faces Nasdaq Minimum Bid Price Deficiency, Retains Listing Through Compliance Window
- Inspira Technologies receives approval from Clalit for ART100 deployment